NewsBenzingaCardiol Therapeutics annonce des progrès dans l'inscription et prévoit d'élargir son essai de phase III MAVERIC évaluant CardiolRx pour la réduction du risque de récurrence chez les patients atteints de péricardite récurrente Cardiol Therapeutics annonce des progrès dans l'inscription et prévoit d'élargir son essai de phase III MAVERIC évaluant CardiolRx pour la réduction du risque de récurrence chez les patients atteints de péricardite récurrente Benzinga 2026.09.23 10:02 (GMT+0) Open on Benzinga Other news JP Morgan Upgrades Intel to Neutral, Maintains Price Target to $85 Stock Market Today: Dow Jones, S&P 500 Futures Rise as Scott Bessent Links September Inflation to 'Energy Shock' — RCAT, ESLT, STLD in Focus Morgan Stanley Initiates Coverage On Rush Street Interactive with Equal-Weight Rating, Announces Price Target of $22 Winter Storm Watch: Alaska Braces For Up To 36 Inches Of Snow As NWS Warns Of ‘Very Difficult to Impossible’ Travel Jeff Bezos’ Florida Real Estate Empire Could Be Growing With $69 Million Golden Beach Mansion: Report China's Central Bank: Do a Good Job in Financial Support for the Development of the AI Industry
Stock Market Today: Dow Jones, S&P 500 Futures Rise as Scott Bessent Links September Inflation to 'Energy Shock' — RCAT, ESLT, STLD in Focus
Morgan Stanley Initiates Coverage On Rush Street Interactive with Equal-Weight Rating, Announces Price Target of $22
Winter Storm Watch: Alaska Braces For Up To 36 Inches Of Snow As NWS Warns Of ‘Very Difficult to Impossible’ Travel
Jeff Bezos’ Florida Real Estate Empire Could Be Growing With $69 Million Golden Beach Mansion: Report
